Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $0.38.

  • Amphastar Pharmaceuticals' EPS (Basic) fell 5421.69% to $0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.36, marking a year-over-year decrease of 2738.46%. This contributed to the annual value of $3.29 for FY2024, which is 1543.86% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its EPS (Basic) stood at $0.38 for Q3 2025, which was down 5421.69% from $0.66 recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' EPS (Basic) registered a high of $1.01 during Q3 2023, and its lowest value of $0.11 during Q1 2021.
  • Its 5-year average for EPS (Basic) is $0.57, with a median of $0.54 in 2023.
  • In the last 5 years, Amphastar Pharmaceuticals' EPS (Basic) surged by 67500.0% in 2021 and then tumbled by 5421.69% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' EPS (Basic) (Quarter) stood at $0.41 in 2021, then soared by 70.73% to $0.7 in 2022, then increased by 7.14% to $0.75 in 2023, then increased by 5.33% to $0.79 in 2024, then plummeted by 51.9% to $0.38 in 2025.
  • Its EPS (Basic) stands at $0.38 for Q3 2025, versus $0.66 for Q2 2025 and $0.53 for Q1 2025.